NADOLOL
Generic: NADOLOL
Alembic Pharmaceuticals LimitedManufacturer
ORALRoute
NADOLOLActive Substance
2023-06-02Original Approval
NADOLOL is FDA application ANDA211763, sponsored by ALEMBIC. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Top Reported Reactions
1
DRUG INEFFECTIVE
1,307 reports
2
MACULAR DEGENERATION
831 reports
3
NAUSEA
675 reports
4
HEADACHE
608 reports
5
OFF LABEL USE
607 reports
6
FATIGUE
530 reports
7
PAIN
514 reports
8
WEIGHT DECREASED
463 reports
9
DIARRHOEA
444 reports
10
MALAISE
421 reports